GlassScriptPhysician profile
Gina M Keep
NPI 1275510521
$17,490.10
in general payments reported to CMS, 2019-2025
43 companies · $2,755 in 2025
The $2,755 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,693 · 2022: $4,370 · 2023: $3,835 · 2024: $2,838 · 2025: $2,755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,403 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,402.52 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,995.49 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,427.51 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $1,937.19 | 2021-2024 | Arexvy, Trelegy Ellipta, Nucala |
| Amgen INC. | $1,116.04 | 2021-2025 | Repatha, Repatha, Evenity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $933.44 | 2021-2024 | Xifaxan |
| Lilly USA, LLC | $845.89 | 2021-2024 | Mounjaro, Jardiance, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $546.91 | 2021-2024 | Jardiance, Cyltezo, Synjardy |
| Regeneron Healthcare Solutions, INC. | $542.91 | 2023-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $490.84 | 2021-2023 | Entyvio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $417.34 | 2023-2025 | Caplyta |
| Axsome Therapeutics, INC. | $394.36 | 2025 | Auvelity |
| Genzyme Corporation | $335.70 | 2021-2025 | |
| Intercept Pharmaceuticals, INC. | $317.83 | 2022-2023 | Ocaliva |
| Sumitomo Pharma America, INC. | $274.80 | 2023-2024 | Gemtesa |
| Intra-Sana Laboratories | $223.97 | 2023-2024 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $208.03 | 2021-2023 | Nexletol, Contrave |
| Idorsia Pharmaceuticals US INC | $195.11 | 2023 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $191.75 | 2023-2024 | Rexulti |
| Merck Sharp & Dohme LLC | $156.88 | 2021-2023 | Dificid |
| Ironwood Pharmaceuticals, INC | $154.19 | 2021-2023 | Linzess |
| Acadia Pharmaceuticals INC | $154.19 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $153.88 | 2021-2023 | Xarelto |
| Novo Nordisk INC | $148.24 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Biohaven Pharmaceutical Holding Company LTD. | $146.76 | 2022 | |
| Xeris Pharmaceuticals, INC. | $142.14 | 2025 | Recorlev |
| Novartis Pharmaceuticals Corporation | $113.67 | 2022-2025 | |
| Redhill Biopharma INC. | $106.03 | 2021-2022 | |
| Lundbeck LLC | $101.46 | 2024-2025 | Rexulti |
| Janssen Biotech, INC. | $91.63 | 2022-2023 | Stelara, Remicade, Simponi Aria |
| Astellas Pharma US INC | $89.19 | 2022-2025 | Veozah |
| Ardelyx, INC. | $88.48 | 2022-2023 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $64.61 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $58.53 | 2021 | |
| Amarin Pharma, INC. | $56.75 | 2021-2022 | |
| Esperion Therapeutics, INC. | $38.26 | 2024-2025 | Nexletol |
| Biogen, INC. | $37.69 | 2021 | |
| Evoke Pharma, INC. | $33.05 | 2021 | |
| Arbor Pharmaceuticals, INC. | $32.40 | 2021 | |
| Vivus LLC | $31.40 | 2021-2022 | |
| Daiichi Sankyo INC. | $28.46 | 2025 | Injectafer |
| E.R. Squibb & Sons, L.L.C. | $24.77 | 2022 | |
| Corium, LLC | $23.89 | 2023 | Adlarity |
| Cmp Pharma, INC. | $18.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gina Keep listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.